Company profile: 4P Therapeutics
1.1 - Company Overview
Company description
- Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4P Therapeutics
GlycoEra
HQ: Switzerland
Website
- Description: Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoEra company profile →
Palo Biofarma
HQ: Spain
Website
- Description: Provider of adenosine receptor-modulating drug discovery and development, with a pipeline including PBF-680 (A1 antagonist, Phase II for asthma/COPD), PBF-999 (PDE-10 inhibitor, Phase II for Prader-Willi syndrome), PBF-1129 (A2b antagonist for idiopathic pulmonary fibrosis and lung cancer), PBF-1650 (A3 antagonist for psoriasis), PBF-677 (A3 antagonist for ulcerative colitis), and PBF-999 dual (PDE10/A2a, Phase I for solid tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palo Biofarma company profile →
Xenetic Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drugs, cancer therapies and vaccines, centered on a DNase I oncology platform and NETs-targeting approaches for pancreatic and other solid tumors; collaborates with Volition on NETs-targeted adoptive cell therapies; holds sublicenses for PolyXen technology for blood/bleeding disorders and DNase enzyme-based cancer treatments; contracts cGMP manufacturing of recombinant Human DNase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenetic Biosciences company profile →
CorMedix
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products targeting cardiac, renal, and infectious diseases. Offers DefenCath, a catheter lock solution with taurolidine and heparin to reduce catheter-related bloodstream infections in adult patients with kidney failure on chronic hemodialysis via central venous catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CorMedix company profile →
Halia Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for inflammatory and neurodegenerative disorders, including HT-6184, a novel NEK7/NLRP3 inhibitor in Phase II for lower-risk myelodysplastic syndromes and post-procedure diagnostic biomarkers of inflammation and pain. Pipeline includes NEK7 inhibitors to block NLRP3 inflammasome assembly and LRRK2 inhibitors for diseases such as Parkinson's and Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halia Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4P Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4P Therapeutics
2.2 - Growth funds investing in similar companies to 4P Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4P Therapeutics
4.2 - Public trading comparable groups for 4P Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →